Everything below concerns RP-HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-04. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
=== Cryo-EM Facility === The cryo-EM facility at the Life Sciences Institute offers a wide range of advanced microscopes and technologies for cryo-electron microscopy, cryo-electron tomography, and correlative light and electron microscopy (CLEM).
These are mostly single-die LEDs used as indicators, and they come in various sizes from 1.8 mm to 10 mm, through-hole and surface mount packages. Typical current ratings range from around 1 mA to above 20 mA. LED's can be soldered to a flexible PCB strip to form LED tape popularly used for decoration. Common package shapes include round, with a domed or flat top, rectangular with a flat top (as used in bar-graph displays), and triangular or square with a flat top. The encapsulation may also be clear or tinted to improve contrast and viewing angle. Infrared devices may have a black tint to block visible light while passing infrared radiation, such as the Osram SFH 4546. 5 V and 12 V LEDs are ordinary miniature LEDs that have a series resistor for direct connection to a 5 V or 12 V supply.
== E == E. coli - Ecotin - EIF-W2 protein domain - electrophoresis - electroporation - ELFV dehydrogenase - Ellis–van Creveld syndrome - end labeling - endonuclease - enhancer - enterobacter ribonuclease - enzyme - epitope - ethidium bromide - evolutionary clock - evolutionary footprinting - exon - exonuclease - exosome complex - expression - expression clone - expression vector - extended ELM2 domain -
American Chemical Society Award in Chromatography and Electrophoresis (1964) with Stanford Moore Richards Medal of the American Chemical Society (1972) with Stanford Moore Kaj Linderstrøm-Lang Award, Copenhagen (1972) with Stanford Moore The Nobel Prize in Chemistry (1972) with Stanford Moore and Christian B. Anfinsen
=== Coffee consumption === Epidemiological studies show that coffee consumption is associated with decreased mortality and lower rates of some neurological diseases, including Parkinson's disease and type 2 diabetes. Coffee beans and roasted coffee can contain hundreds of individual compounds, including caffeine, chlorogenic acid (CGA), quercetin, trigonelline, caffeic acid, and phenylindane. Underlying mechanisms are not yet understood.
Sources: en.wikipedia.org
== Education and career == In 1987, Viswanathan completed his MBBS degree from Govt. Stanley Medical College. He later went on to pursue his MD in Internal Medicine at the Kasturba Medical College, Mangalore, which he completed in 1991. In 1999, Viswanathan earned his Ph.D. in Diabetic Nephropathy from The Tamil Nadu Dr. M.G.R. Medical University (TNMGRMU). Additionally, he has advanced post-graduate training in diabetes. In 2010, Viswanathan completed his FRCP from the Royal College of Physicians in London. He serves as the President of Prof. M. Viswanathan Diabetes Research Centre, a WHO Collaborating centre for Research, Education and Training, and a Scientific & Industrial Research Organization (SIRO) recognized by the Department of Scientific and Industrial Research (Govt. of India). In 2019, he was the National Vice President of the Research Society for the Study of Diabetes (RSSDI). Viswanathan is a member of the European Association for the Study of Diabetes (EASD), the European Association for Study of Diabetes (EASD) as well as the European Diabetic Nephropathy Study Group (EDNSG). Additionally, he is a founding member of the Diabetic Foot Study Group (DFSG). Viswanathan was involved in drafting guidelines for wound healing and offloading as part of The International Working Group on the Diabetic Foot (IWGDF) will release these guidelines next year, which are updated every four years. Viswanathan has previously drafted infection guidelines in 2015 and recommendations for footwear for diabetic foot ulcers in 2019.
The three substrates of this enzyme are saccharopine, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are L-lysine, reduced NADH, α-ketoglutaric acid, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is N6-(L-1,3-dicarboxypropyl)-L-lysine:NAD+ oxidoreductase (L-lysine-forming). Other names in common use include lysine-2-oxoglutarate reductase, dehydrogenase, saccharopine (nicotinamide adenine dinucleotide,, lysine forming), epsilon-N-(L-glutaryl-2)-L-lysine:NAD oxidoreductase (L-lysine, forming), N6-(glutar-2-yl)-L-lysine:NAD oxidoreductase (L-lysine-forming), 6-N-(L-1,3-dicarboxypropyl)-L-lysine:NAD+ oxidoreductase, and (L-lysine-forming). This enzyme participates in lysine biosynthesis and lysine degradation.
SDS-PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis) is a discontinuous electrophoretic system developed by Ulrich K. Laemmli which is commonly used as a method to separate proteins with molecular masses between 5 and 250 kDa. The combined use of sodium dodecyl sulfate (SDS, also known as sodium lauryl sulfate) and polyacrylamide gel eliminates the influence of structure and charge, and proteins are separated by differences in their size. As of 2025, the publication describing it was the most frequently cited paper by a single author, and the second most cited overall - with over 259,000 citations.
== Steered molecular dynamics (SMD) == Steered molecular dynamics (SMD) simulations, or force probe simulations, apply forces to a protein in order to manipulate its structure by pulling it along desired degrees of freedom. These experiments can be used to reveal structural changes in a protein at the atomic level. SMD is often used to simulate events such as mechanical unfolding or stretching. There are two typical protocols of SMD: one in which pulling velocity is held constant, and one in which applied force is constant. Typically, part of the studied system (e.g., an atom in a protein) is restrained by a harmonic potential. Forces are then applied to specific atoms at either a constant velocity or a constant force. Umbrella sampling is used to move the system along the desired reaction coordinate by varying, for example, the forces, distances, and angles manipulated in the simulation. Through umbrella sampling, all of the system's configurations—both high-energy and low-energy—are adequately sampled. Then, each configuration's change in free energy can be calculated as the potential of mean force. A popular method of computing PMF is through the weighted histogram analysis method (WHAM), which analyzes a series of umbrella sampling simulations. A lot of important applications of SMD are in the field of drug discovery and biomolecular sciences. For e.g.
Federal Prime Minister Milan Panić became frustrated with Milošević's domineering behaviour during diplomatic talks in 1992 and told Milošević to "shut up" because Milošević's position was officially subordinate to his position. Milošević later forced Panić to resign. This situation changed after 1997 when Milošević's second and last legal term as Serbian President ended. He then had himself elected Federal President, thus entrenching the power that he already de facto held. After the Federal Republic was reconstituted as a State Union, the new Assembly of the State Union was created. It was unicameral and was made up of 126 deputies, of which 91 were from Serbia and 35 were from Montenegro. The Assembly convened in the building of the old Federal Assembly of Yugoslavia, which now houses the National Assembly of Serbia. A direct, nationwide election was planned for 2005, but was subsequently delayed to 2006 in Montenegro and 2007 in Serbia to coincide with local parliamentary elections. Since the State Union dissolved before either was held, direct parliamentary elections were never held and the deputies were instead elected indirectly by the parliament of their respective republic. In 2003, after the constitutional changes and creation of the State Union of Serbia and Montenegro, a new President of Serbia and Montenegro was elected. He was also president of the Council of Ministers of Serbia and Montenegro. Svetozar Marović was the first and last President of Serbia and Montenegro until its breakup in 2006.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.